Soaring Demand Set to Propel Inactivated Influenza Vaccine Market to $9.77 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Inactivated Influenza Vaccine Market Through 2025?
The market for inactivated influenza vaccines has seen significant expansion over the past few years. The value will surge from $6.62 billion in 2024, reaching up to $7.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.8%. Factors accounting for this growth throughout the preceding years include heightened instances of seasonal flu outbreaks, governmental vaccination initiatives, escalating numbers in the aging population, enhanced awareness towards public health and greater resources in healthcare infrastructure.

What's the Projected Size of the Global Inactivated Influenza Vaccine Market by 2029?
Anticipated to see significant growth in the next few years, the market size of the inactivated influenza vaccine is projected to expand to $9.77 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.1%. The expected increase in this period can be credited to factors such as the escalating demand for quadrivalent vaccines, broadening immunization schemes, an intensified focus on strategies for pandemic readiness, advancements in vaccine production technology, as well as the growth in global access to vaccines. Prime trends during this forecast period encapsulate a shift towards the production of cell-based vaccines, an upsurge in the adoption of adjuvanted formulations, combination of influenza vaccines with COVID-19 boosters, increased demand within emerging markets, and tailoring vaccine development strategies as per individual needs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/inactivated-influenza-vaccine-global-market-report

Top Growth Drivers in the Inactivated Influenza Vaccine Industry: What's Accelerating the Market?
The increase in government-sponsored vaccination initiatives is anticipated to drive the expansion of the inactivated influenza vaccine market. The proliferation of these programs is spurred by growing public health consciousness among communities, which results in a surge in demand for vaccination services, prompting governments to improve the availability and reach of vaccines. Government vaccination programs enable equitable distribution and administration of inactivated influenza vaccines by offering them freely, or at subsidized costs to vulnerable demographics, effectively ensuring inclusive vaccination coverage and alleviating the impact of seasonal flu. To exemplify, the National Health Service, a government body based in the UK, launched an NHS vaccine policy for vaccination objectives in December 2023. The policy comprises plans for delivering vaccines in local communities, with a particular emphasis on disadvantaged and neglected groups. Consequently, the upsurge in government vaccination schemes is fuelling the development of the inactivated influenza vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24251&type=smp

What Long-Term Trends Will Define the Future of the Inactivated Influenza Vaccine Market?
Leading businesses in the inactivated influenza vaccine market are prioritizing the development of quadrivalent inactivated influenza vaccines in order to offer extensive protection against four variations of the flu virus. A quadrivalent inactivated influenza vaccine is a type of flu shot that defends against four distinctive flu viruses. For example, Zydus Lifesciences, a pharmaceutical company based in India, introduced VaxiFlu-4, a quadrivalent inactivated influenza vaccine developed specifically to provide seasonal defence against four emerging virus strains, in February 2025. VaxiFlu-4 offers a wider scope of protection that encompasses both influenza A and B strains, diminishing the chances of vaccine mismatch. This vaccine is aimed at handling seasonal flu epidemics with an enhanced immune response adapted to local epidemiological trends.

What Are the Main Segments in the Inactivated Influenza Vaccine Market?
The inactivated influenza vaccine market covered in this report is segmented -

1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV), Quadrivalent Inactivated Influenza Vaccine (QIIV)
2) By Application: Children, Adolescence, Adults, Elderly
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Clinics
4) By End-User: Healthcare Providers, Individuals, Government Organizations, Pharmaceutical Companies

Subsegments:
1) Trivalent Inactivated Influenza Vaccine (TIIV): Egg-based Trivalent Inactivated Influenza Vaccine, Cell-based Trivalent Inactivated Influenza Vaccine, Adjuvanted Trivalent Inactivated Influenza Vaccine, High-dose Trivalent Inactivated Influenza Vaccine
2) Quadrivalent Inactivated Influenza Vaccine (QIIV): Egg-based Quadrivalent Inactivated Influenza Vaccine, Cell-based Quadrivalent Inactivated Influenza Vaccine, Adjuvanted Quadrivalent Inactivated Influenza Vaccine, Recombinant Quadrivalent Inactivated Influenza Vaccine, Pediatric Quadrivalent Inactivated Influenza Vaccine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24251&type=smp

Which Top Companies are Driving Growth in the Inactivated Influenza Vaccine Market?
Major companies operating in the inactivated influenza vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis International, GlaxoSmithKline plc, Viatris Inc., CSL, Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Dalian Aleph Biomedical Co. Ltd., Hualan Biological Bacterin Co. Ltd, Changchun Biological, Jiangsu gdk Biotechnology Co., Ltd., KM Biologics, JoinHub Pharma, Pharmika India Private Limited.

Which Regions Will Dominate the Inactivated Influenza Vaccine Market Through 2029?
North America was the largest region in the inactivated influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated influenza vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24251

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.